Rezolute combines a business quality score far below the required floor, a confirmed price downtrend, high short interest, and repeated earnings misses, consistent with the binary clinical-stage risk profile behind a call to exit the position.
Thesis pillars
- Quality Below Minimum Floor→Stable
- Confirmed Downtrend With Overbought Bounce↑Improving
- High Short Interest And Binary Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Sep 24, 2026
Rezolute, Inc. (RZLT) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $4.22: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality.
Rezolute is a late-stage rare disease company developing ersodetug, an intravenous monoclonal antibody for refractory hypoglycemia caused by congenital and tumor-related hyperinsulinism. It has no marketed products or reported revenue, funds operations from cash and investments,... Read more
Sell if holding. Engine safety override at $4.22: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality. Chart setup: RSI 41 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 7d<=7d. Suitability: speculative.
About Rezolute, Inc.
About Rezolute, Inc.
Rezolute is advancing ersodetug, its lead antibody candidate, through two pivotal Phase 3 trials for hyperinsulinism-driven hypoglycemia: sunRIZE, which completed enrollment of more than 56 participants across a dozen countries in May 2025, and upLIFT, a truncated single-arm study for tumor HI. The company incurred $61.5 million in research and development expense in fiscal 2025 and reported a $403.9 million accumulated deficit as of June 30, 2025, with no approved products generating revenue yet.
Rezolute holds a worldwide, exclusive license from XOMA covering the ersodetug molecule, including 38 issued patents that expire between 2030 and 2036, and relies on a small number of third-party suppliers for raw materials used in clinical and future commercial manufacturing. The company depends on outside contract research organizations to run its clinical trials rather than conducting them in-house, ceding some control over trial timing, data collection, and regulatory reporting. Ersodetug has received Orphan Drug Designation, Rare Pediatric Disease Designation, and Breakthrough Therapy Designation from the FDA, plus PRIME designation from the European Medicines Agency, positioning it for expedited review once pivotal data reads out. Competing hyperinsulinism programs are under development at Amylyx Pharmaceuticals, Hanmi Pharmaceuticals, and Zealand Pharma. As of September 15, 2025, Rezolute employed 77 full-time staff, most in research and development, reflecting its focus on clinical execution rather than commercial infrastructure.
Show full overview
Rezolute's near-term valuation hinges almost entirely on binary trial readouts rather than a diversified pipeline: topline sunRIZE data were anticipated in December 2025, and upLIFT results are expected in the second half of calendar 2026, with no other late-stage asset to offset a negative outcome on either study. The 10-K also flags reliance on external contract manufacturers for both raw materials and any future commercial-scale production, since Rezolute has no in-house commercial manufacturing experience. With $167.9 million in cash and marketable securities against a $403.9 million accumulated deficit, a delayed or failed readout would compress the runway management says covers at least 12 months from the filing date.
See also: Healthcare · Biotechnology
From Rezolute, Inc.'s most recent 10-K filing, extracted October 18, 2026.
Recent developments
updated 2026-10-29Recent Developments — Rezolute, Inc.
Latest news
- NEWS Rezolute Completes Enrollment In Open-Label Phase 3 Study Of Ersodetug In Tumor HI; Topline Data Expected In Mid-Decembe — benzinga Oct 14, 2026
- NEWS This NetApp Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday — benzinga Oct 7, 2026 neutral
- NEWS Lake Street Maintains Buy on Rezolute, Raises Price Target to $12 — benzinga Oct 6, 2026 positive
- NEWS Citizens Maintains Market Outperform on Rezolute, Raises Price Target to $15 — benzinga Oct 6, 2026 positive
- NEWS This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday — benzinga Oct 6, 2026 positive
Generated 2026-10-29T11:53:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMpipelineersodetug lead clinical asset10-K Item 1: 'Our lead clinical asset, ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism.'
- MEDIUMSuppliersmall number of third-party raw material suppliers10-K Item 1A: 'We rely upon a small number of third-party suppliers for the manufacture of certain raw materials that are necessary to formulate our drug products'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $4.22: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality. Chart setup: RSI 41 mid-range, Bollinger mid-band. Prior stop was $3.92. Score 5.3/10, moderate confidence.
Analyst target: $8.53 (+102.0% upside). Prior stop was $3.92. Stop-loss: $3.92.
Quality below floor (1.6 < 4.0); Value-trap signals (2/5): Margin compression (op margin -62.9%), Material insider selling (8 sells, 3.50% of cap).
Rezolute, Inc. trades at a P/E of N/A (forward -9.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
17 analysts cover RZLT with a consensus score of 4.2/5. Average price target: $10.
What does Rezolute, Inc. do?Rezolute is a late-stage rare disease company developing ersodetug, an intravenous monoclonal antibody for refractory...
Rezolute is a late-stage rare disease company developing ersodetug, an intravenous monoclonal antibody for refractory hypoglycemia caused by congenital and tumor-related hyperinsulinism. It has no marketed products or reported revenue, funds operations from cash and investments, and spent $53.8 million on R&D in fiscal 2026. Ersodetug holds FDA Breakthrough Therapy and Orphan Drug designations for congenital hyperinsulinism.